(12 Aug 2024, 09:14)

Dr Reddy's formulations manufacturing units receives EIR from USFDA

Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

Dr Reddys Laboratories has received the Establishment Inspection Report (EIR) for its formulations manufacturing facilities (FTO-7 & FTO-9) in Duvvada, Visakhapatnam. The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed" under 21 CFR 20.64(d)(3).

More News

(28-Aug-2024 09:06)
Shares of Orient Technologies list today
(28-Aug-2024 09:09)
PDS concludes QIP issue with fund raise of Rs 430 cr
(28-Aug-2024 09:12)
PDS allots 80.22 lakh equity shares under QIP issue
(28-Aug-2024 09:32)
Infibeam's first AI product 'AI Facility Manager' secures multiple contracts

More Company News View Company Information

Hot Pursuit (24-Aug-2024 14:50)
DRL's Andhra Pradesh facility gets 3 observations from USFDA
Hot Pursuit (21-Aug-2024 13:05)
Dr Reddys Laboratories Ltd gains for third straight session
Corporate News (12-Aug-2024 09:14)
Dr Reddy's formulations manufacturing units receives EIR from USFDA
Corporate News (07-Aug-2024 18:13)
Dr Reddys allots 29,790 equity shares under ESOP
Corporate News (29-Jul-2024 09:15)
Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Results - Announcements (27-Jul-2024 16:55)
Dr Reddy's Laboratories consolidated net profit declines 0.90% in the June 2024 quarter
Corporate News (19-Jul-2024 09:46)
Dr. Reddy's inks patent licensing agreement with Takeda

Corporate News

Dr Reddy's formulations manufacturing units receives EIR from USFDA